Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 3/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 12/20 | 0.38 |
| ▸ | JAK3 | P52333 | 12/20 | 0.38 |
| ▸ | JAK1 | P23458 | 11/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14697453 | 0.98 | TYMP (0.47) | TYMPGSK3BBACE1DYRK1APRKCI | |
| SCHEMBL2316792 | 0.81 | JAK2 (0.45) | TYMPGSK3BBACE1DYRK1APRKCI | |
| SCHEMBL29588095 | 0.79 | PRKCI (0.42) | DYRK1APRKCIAXLJAK2JAK3 | |
| Hydrochloric Acid SCHEMBL29587391 | 0.78 | PRKCI (0.41) | DYRK1APRKCIAXLJAK2JAK3 | |
| SCHEMBL14697441 | 0.75 | CCR8 (0.52) | DYRK1APRKCIAXLJAK2JAK3 | |
| SCHEMBL20967693 | 0.74 | JAK1 (0.54) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL17353634 | 0.72 | PRKCI (0.42) | DYRK1APRKCIAXLJAK2JAK3 | |
| SCHEMBL2021911 | 0.71 | PARP1 (0.47) | — | |
| SCHEMBL14697443 | 0.71 | PRKCI (0.41) | DYRK1APRKCIAXLJAK2JAK3 | |
| SCHEMBL3238795 | 0.70 | GSK3B (0.53) | TYMPGSK3BBACE1DYRK1AGDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022155202-A1 | FUSED HETEROCYCLES AND USES OF SAME | SCHRÖDINGER, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| EP-2742049-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | TYMP 657/4885GSK3B 163/4885BACE1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.